Cell Therapy Manufacturing Market
Discover How Programmable Cell Therapies Can Help Mankind to Fight Genetic Conditions like Sickle Cell Anemia in FMI’s Report!
Cell Therapy Manufacturing Market by Source, Indication, Manufacturing Purpose, Route of Administration, Cell Type, End User & Region - Forecast 2022 - 2032
Cell Therapy Manufacturing Market Outlook (2022-2032)
[250 Pages Report] The global cell therapy manufacturing market size is expected to reach a valuation of US$ 3.7 Bn by the end of 2022 and further expand at a CAGR of 14.2% from 2022-2032. The market is anticipated to reach a valuation of ~US$ 13.9 Bn by the end of 2032. Autologous cell therapy manufacturing is leading the global market and held a share of about 56.0% in 2021.
A sophisticated gene-edited cell-based product such as chimeric antigen receptor (CAR)-T cells or tissue engineering products like Holoclar, are examples of modern cell therapies that include but are not limited to blood transfusion and hematopoietic progenitor stem cell transplantation exclusively. Quality standards have evolved in response to the continual improvement of cell therapy manufacturing processes, thereby resulting in improved product consistency, reliability, and efficacy.
Manufacturing processes need a transition from open and manual to closed and automated in order to scale up. This would offer several benefits such as decreased risk of contamination, improved product uniformity, increased efficiency, and surging traceability throughout the process to assure the chain of custody.
In order to reduce risks and get ready for a high production future, groups in both academia and industry are actively implementing novel technologies that can help them build automated, scalable, and closed systems. Key players are also working on the development of innovative technologies that can assist investigators in automating their processes for success in future.
|
Attributes |
Key Statistics |
|
Global Cell Therapy Manufacturing Market Estimated Size (2022E) |
US$ 3.7 Bn |
|
Projected Market Valuation (2032F) |
US$ 13.9 Bn |
|
Value-based CAGR (2022-2032) |
14.2% |
|
Collective Value Share: Top 5 Countries (2022) |
66.3% |
Let us know your requirement to get
100% FREE customization
2012-2021 Cell Therapy Manufacturing Demand Outlook Compared to 2022-2032 Forecast
The cell therapy manufacturing industry held approximately 3.3% of the global targeted therapeutics market, which was worth ~US$ 100.9 Bn in 2021. The global cell therapy manufacturing market expanded at a CAGR of 9.9% from 2012 to 2021 owing to the positive outcomes of immunotherapy.
In its most precise definition, cell therapy manufacturing starts with the patient's cell collection in a clinical (or apheresis) facility and ends with the patient receiving the finished drug at their bedside. Numerous hand-off points and activities occur between the initial raw material collection and the subsequent administration of a product.
Cell therapy manufacturing differs from a more conventional pharmaceutical production due to the complexity of all these working components in a supply chain, as well as the blend of the production and delivery phases. The majority, if not all, cell therapies currently available are only meant to treat a small number of patients.
However, if they are to be made widely accessible for a variety of indications, advancements in automation, process simplification, and supply chain management will be necessary to keep up with the rising demand. Owing to the aforementioned factors, the global cell therapy manufacturing market is expected to surge at a CAGR of 14.2% during the forecast period from 2022 to 2032.
Top Trend Pushing Sales in the Global Cell Therapy Manufacturing Market
- Rising Practice of Manufacturing Capability Outsourcing
It can be challenging and time-consuming for businesses that are not familiar with the cell therapy manufacturing process to build a solid supply chain with tools and processes required to satisfy consumer demand. Companies that have a strong understanding of the biology of their product, but are unfamiliar with how to transition from a small, manual production to a scaled-up, automated production that can serve the needs of hundreds of thousands of patients globally, can quickly bridge the gap with the help of an outside organization, such as a contract manufacturing organization (CMO).
Outsourcing of manufacturing capabilities will create growth opportunities for new industry entrants to scale up their products for wide-scale distribution. Additionally, outsourcing can save manufacturers from making investments on large-scale systems and facilitate in anticipation of future product delays or regulatory denials.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich Factors Are Limiting Demand in the Cell Therapy Manufacturing Industry?
Manufacturers of cell therapies face certain process limitations when they aim to provide a functional and safe output from an extremely variable starting material. Increased starting material variability poses limitations on the production protocols for desired end use products.
Additionally, as different phases in the production of cell therapy require variable timespans, bottlenecks can develop in a fully automated system by holding one part of equipment engaged for a longer duration of time, while the rest of the system sits idle, not utilizing resources and wasting both time & space.
The design is more efficient in a modular system as only one part of the system is engaged and the rest of the system is available for usage. Another drawback of fully automated systems is that they could bind an organization or a research team to a certain methodology.
Country-wise Insights
What Makes the U.S. a Large Market for Cell Therapy Manufacturing?
“Rising Prevalence of Sickle Cell Disease to Fuel Demand for Gene Manufacturing in the U.S.”
The U.S. dominates the North American region and held a total share of about 96.8% in 2021. The country is expected to continue to remain at the forefront throughout the forecast period. Increasing prevalence of sickle cell disease in the country and presence of a large number of gene & cell and tissue-based therapeutic developers are likely to drive growth. As per the Centers for Disease Control and Prevention (CDC), sickle cell disease affects nearly 100,000 Americans and it occurs among about 1 out of every 16,300 Hispanic-American births.
What Makes the U.K. a Highly Lucrative Market for Cell Therapy Manufacturing?
“CAR T Cell Manufacturing to Gain Traction in the U.K.”
The U.K. held approximately 26.6% of share in the Europe market in 2021. The country reflects a lucrative outlook towards cell therapy manufacturing. As per the European Medicines Agency, from 2018 until 2020, nearly 102% of advanced therapy classifications occurred across Europe annually.
What is the Outlook of China in the Cell Therapy Manufacturing Market?
“Cell and Gene Manufacturing Companies in China to Develop New Processing Methods”
China held a share of around 38.2% in 2021 in the East Asia cell therapy manufacturing market, finds FMI. Chinese local biotech businesses are working with industry associations to develop guidelines for maintaining high product quality and introducing new processing methods in an effort to streamline cell therapy manufacturing. For instance, SALIAI, a leading stem cell start-up, is promoting the establishment of production and quality standards for the stem cell sector while collaborating with the China Quality Association for Pharmaceuticals.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Category-wise Insights
Which is the Highly Preferred Source?
“Autologous Cell Therapy to Gain Impetus in the Global Market”
The autologous source segment held the largest share of around 56.0% in 2021. Growth is attributed to various advantages of autologous sources in stem cell transplant. They can help in promoting faster recovery of cell counts, reducing mortality rates associated with the treatment modality, and providing a shorter length of hospital stays.
Which is the Leading Indication Segment?
“Development of Cell Therapy Technology for Cancer to Push the Market”
Cancer is expected to showcase high growth at a CAGR of 14.8% by the end of the forecast period. As per FMI, the segment held a market share of about 31.0% in 2021. High incidence rate of cancer, as well as growing adoption of novel treatment models for targeted therapy are propelling the segment in the global cell therapy manufacturing market.
Which is the Dominant Purpose of Cell Therapy Manufacturing?
“Need for Clinical Manufacturing to Surge in the Next Decade”
For pre-clinical, clinical, and commercial scaling of cell therapy products, manufacturing processes promote adoptive standardization for each protocol. Clinical manufacturing held a high market share of around 42.0% in the global market, followed by commercial manufacturing, which accounted for a share of about 32.0% globally in 2021.
Which Route of Administration is Set to Exhibit Lucrative Growth?
“Stem Cell Manufacturing Companies to Focus on Producing Injectables”
Injectables held a market share of about 44.0% in 2021 in the global market. Injectables promote greater absorption of therapeutic drugs at the target site and hence contribute to a positive outcome for disease treatment. Moreover, injections for cell therapy would exhibit better cell retention at the targeted site of the disease.
Which is the Most Prominent Cell Type?
“Prevalence of Leukemia to Boost Sales of Hematopoietic Stem Cell Manufacturing Companies”
The hematopoietic stem cells (HSC) segment held a share of around 25.0% in 2021 in the cell therapy manufacturing market as many malignant disorders, including leukemia and lymphoma, as well as non-malignant conditions such as sickle cell disease, are treated with HSCs in order to replace or rebuild the patient's hematopoietic system.
Which End User Would Benefit the Most in the Global Market?
“Cell Therapy Logistics to Target Hospital Settings”
Hospital settings held the highest market share of around 38.1% in 2021, says FMI. This segment is emerging as a valuable end user with the advancement of point-of-care manufacturing of cell therapies in units close to hospital settings for increased accessibility of treatment, as well as to reduce treatment time and risk of contamination.
Competitive Landscape
The global cell therapy manufacturing market is fragmented with the presence of a large number of companies. They are striving persistently to build digital capabilities for cell therapy production. These efforts would help them to optimize their business processes and expand their portfolios in the global market.
For instance,
- In April 2022, Lonza added additional integrated capabilities in cell separation, bead removal, and cell binding with the release of its second-generation instrument. It would help in extending the functionality of the company’s Cocoon Platform with magnetic selection capability for cell therapy manufacturing.
- In April 2022, Catalent acquired Erytech Pharma for its industrial-scale cell therapy production plant in Princeton, New Jersey. The arrangement includes an exclusive long-term supply partnership, thereby enabling Catalent to promote red blood cell-derived therapy, eryaspase (GRASPA) by Erytech for acute lymphoblastic leukemia.
Scope of the Report
|
Attribute |
Details |
|
Estimated Market Size (2022) |
US$ 3.7 Bn |
|
Projected Market Valuation (2032) |
US$ 13.9 Bn |
|
Value-based CAGR (2022 to 2032) |
14.2% |
|
Forecast Period |
2022-2032 |
|
Historical Data Available for |
2012-2021 |
|
Market Analysis |
Value (US$ Bn) |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
|
Key Countries Covered |
U.S., Canada, Brazil, Mexico, Argentina, U.K., Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, North Africa, and South Africa |
|
Key Market Segments Covered |
Source, Indication, Manufacturing Purpose, Route of Administration, Cell Type, End User, Region |
|
Key Companies Profiled |
|
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
Key Segments Covered in Cell Therapy Manufacturing Industry
By Source:
- Autologous
- Allogenic
By Indication:
- HIV
- Autoimmune Disorders
- Immune Deficiencies
- Cancer
- Neurological Disorders
By Manufacturing Purpose:
- Clinical
- Commercial
- Pre-clinical
By Route of Administration:
- Topical
- Injectable
- Infusion
- Implantable Bio-Scaffold
By Cell Type:
- Hematopoietic (Blood-Forming) Stem Cells (HSC)
- Skeletal Muscle Stem Cells
- Mesenchymal Stem Cells
- Lymphocytes
- Dendritic Cells
- Pancreatic Islet Cells
- CAR-T Cells
By End User:
- Hospital Settings
- Intensive Outpatient Treatment Centers
- Academic and Research Institutes
- Specialty Clinics
By Region :
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Frequently Asked Questions
The global market was worth US$ 3.3 Bn in 2021 and is set to expand 3.8X over the next ten years.
The market is expected to reach US$ 13.9 Bn by the end of 2032 and exhibit growth at a CAGR of 14.2% from 2022-2032.
Emergence of CMO/CDMO, rising demand for novel disease therapeutics, and growing regulatory approvals for new products are some of the key trends in this market.
North America held the highest market share of around 43.5% in 2021.
Europe accounted for about 29.3% of the global market in 2021 and is projected to grow at a CAGR of 14.3% during the forecast period.
The U.S., the U.K., Germany, Japan, and France are the top five countries driving demand in the global market.
Merck KGaA, Avantor, Inc., Cell Therapies Pty Ltd, Thermo Fisher Scientific, Charles River Laboratories, Catalent, Inc, Bio-Techne, Cytiva, Lonza, The Discovery Labs, and BIOCENTRIQ are some of the key players in the industry.
From 2012-2021, the market expanded at a CAGR of 9.9%.
South Asia accounted for 7.4% of the market share in 2021 and is expected to grow at 19.1% CAGR during the forecast period.
East Asia is set to exhibit a lucrative CAGR of 21.2% during the forecast period.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Market Innovation / Development Trends
4. Key Success Factors
4.1. Source Pipeline
4.2. Promotional Strategies, By Key Manufacturers
4.3. Key Regulations
4.4. Value Chain Analysis
4.5. PESTEL Analysis
4.6. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Targeted Therapeutics Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Adoption of Automated Resources
5.2.2. Prevalence of Chronic Diseases
5.2.3. Regulatory Impositions
5.2.4. Reimbursement Scenario
5.2.5. Growth in Biopharma Production
5.2.6. Outsourcing of Manufacturing Capabilities
5.2.7. Expected Source Launches
5.2.8. Research and Development
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Source
6.1.2. By Indication
6.1.3. By Manufacturing Purpose
6.1.4. By Route of Administration
6.1.5. By Cell Type
6.1.6. By End User
6.1.7. By Country
6.2. 2021 Market Scenario
7. Global Cell Therapy Manufacturing Market Demand (in Value or Size in US$ Bn) Analysis 2012–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Bn) Analysis, 2012-2021
7.2. Current and Future Market Value (US$ Bn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Cell Therapy Manufacturing Market Analysis 2012-2021 and Forecast 2022–2032, By Source
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Source, 2012 - 2021
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Source, 2022 - 2032
8.3.1. Autologous
8.3.2. Allogenic
8.4. Market Attractiveness Analysis By Source
9. Global Cell Therapy Manufacturing Market Analysis 2012-2021 and Forecast 2022–2032, By Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis By Indication , 2012 - 2021
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Indication, 2022 - 2032
9.3.1. HIV
9.3.2. Autoimmune Disorders
9.3.3. Immune Deficiencies
9.3.4. Cancer
9.3.5. Neurological Disorders
9.4. Market Attractiveness Analysis By Indication
10. Global Cell Therapy Manufacturing Market Analysis 2012-2021 and Forecast 2022–2032, By Manufacturing Purpose
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis By Manufacturing Purpose, 2012 - 2021
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Manufacturing Purpose, 2022 - 2032
10.3.1. Clinical
10.3.2. Commercial
10.3.3. Pre-clinical
10.4. Market Attractiveness Analysis By Manufacturing Purpose
11. Global Cell Therapy Manufacturing Market Analysis 2012-2021 and Forecast 2022–2032, By Route of Administration
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Bn) Analysis By Route of Administration, 2012 - 2021
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Route of Administration, 2022 - 2032
11.3.1. Topical
11.3.2. Injectable
11.3.3. Infusion
11.3.4. Implantable Bio-Scaffold
11.4. Market Attractiveness Analysis By Route of Administration
12. Global Cell Therapy Manufacturing Market Analysis 2012-2021 and Forecast 2022–2032, By Cell Type
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Bn) Analysis Cell Type, 2012 - 2021
12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Cell Type, 2022 - 2032
12.3.1. Hematopoietic (Blood-Forming) Stem Cells (HSC)
12.3.2. Skeletal Muscle Stem Cells
12.3.3. Mesenchymal Stem Cells
12.3.4. Lymphocytes
12.3.5. Dendritic Cells
12.3.6. Pancreatic Islet Cells
12.3.7. CAR-T Cells
12.4. Market Attractiveness Analysis By Cell Type
13. Global Cell Therapy Manufacturing Market Analysis 2012-2021 and Forecast 2022–2032, By End User
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Bn) Analysis By End User, 2012 - 2021
13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By End User, 2022 - 2032
13.3.1. Hospital Settings
13.3.2. Intensive Outpatient Treatment Centers
13.3.3. Academic and Research Institutes
13.3.4. Specialty Clinics
13.4. Market Attractiveness Analysis By End User
14. Global Cell Therapy Manufacturing Market Analysis 2012-2021 and Forecast 2022–2032, By Region
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Bn) Analysis By Region, 2012-2021
14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2022–2032
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. East Asia
14.3.5. South Asia
14.3.6. Oceania
14.3.7. Middle East and Africa
14.4. Market Attractiveness Analysis By Region
15. North America Cell Therapy Manufacturing Market Analysis 2012–2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012–2021
15.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.1.1. U.S.
15.3.1.2. Canada
15.3.2. By Source
15.3.3. By Indication
15.3.4. By Manufacturing Purpose
15.3.5. By Route of Administration
15.3.6. By Cell Type
15.3.7. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Source
15.4.3. By Indication
15.4.4. By Manufacturing Purpose
15.4.5. By Route of Administration
15.4.6. By Cell Type
15.4.7. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. U.S. Cell Therapy Manufacturing Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast By Market Taxonomy
15.8.1.2.1. By Source
15.8.1.2.2. By Indication
15.8.1.2.3. By Manufacturing Purpose
15.8.1.2.4. By Route of Administration
15.8.1.2.5. By Cell Type
15.8.1.2.6. By End User
15.8.2. Canada Cell Therapy Manufacturing Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast By Market Taxonomy
15.8.2.2.1. By Source
15.8.2.2.2. By Indication
15.8.2.2.3. By Manufacturing Purpose
15.8.2.2.4. By Route of Administration
15.8.2.2.5. By Cell Type
15.8.2.2.6. By End User
16. Latin America Cell Therapy Manufacturing Market Analysis 2012–2021 and Forecast 2022–2032
16.1. Introduction
16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012–2021
16.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032
16.3.1. By Country
16.3.1.1. Mexico
16.3.1.2. Brazil
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Source
16.3.3. By Indication
16.3.4. By Manufacturing Purpose
16.3.5. By Route of Administration
16.3.6. By Cell Type
16.3.7. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Source
16.4.3. By Indication
16.4.4. By Manufacturing Purpose
16.4.5. By Route of Administration
16.4.6. By Cell Type
16.4.7. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Mexico Cell Therapy Manufacturing Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast By Market Taxonomy
16.8.1.2.1. By Source
16.8.1.2.2. By Indication
16.8.1.2.3. By Manufacturing Purpose
16.8.1.2.4. By Route of Administration
16.8.1.2.5. By Cell Type
16.8.1.2.6. By End User
16.8.2. Brazil Cell Therapy Manufacturing Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast By Market Taxonomy
16.8.2.2.1. By Source
16.8.2.2.2. By Indication
16.8.2.2.3. By Manufacturing Purpose
16.8.2.2.4. By Route of Administration
16.8.2.2.5. By Cell Type
16.8.2.2.6. By End User
16.8.3. Argentina Cell Therapy Manufacturing Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast By Market Taxonomy
16.8.3.2.1. By Source
16.8.3.2.2. By Indication
16.8.3.2.3. By Manufacturing Purpose
16.8.3.2.4. By Route of Administration
16.8.3.2.5. By Cell Type
16.8.3.2.6. By End User
17. Europe Cell Therapy Manufacturing Market Analysis 2012–2021 and Forecast 2022–2032
17.1. Introduction
17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012–2021
17.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. U.K.
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Russia
17.3.1.8. Rest of Europe
17.3.2. By Source
17.3.3. By Indication
17.3.4. By Manufacturing Purpose
17.3.5. By Route of Administration
17.3.6. By Cell Type
17.3.7. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Source
17.4.3. By Indication
17.4.4. By Manufacturing Purpose
17.4.5. By Route of Administration
17.4.6. By Cell Type
17.4.7. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Germany Cell Therapy Manufacturing Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast By Market Taxonomy
17.8.1.2.1. By Source
17.8.1.2.2. By Indication
17.8.1.2.3. By Manufacturing Purpose
17.8.1.2.4. By Route of Administration
17.8.1.2.5. By Cell Type
17.8.1.2.6. By End User
17.8.2. Italy Cell Therapy Manufacturing Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast By Market Taxonomy
17.8.2.2.1. By Source
17.8.2.2.2. By Indication
17.8.2.2.3. By Manufacturing Purpose
17.8.2.2.4. By Route of Administration
17.8.2.2.5. By Cell Type
17.8.2.2.6. By End User
17.8.3. France Cell Therapy Manufacturing Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast By Market Taxonomy
17.8.3.2.1. By Source
17.8.3.2.2. By Indication
17.8.3.2.3. By Manufacturing Purpose
17.8.3.2.4. By Route of Administration
17.8.3.2.5. By Cell Type
17.8.3.2.6. By End User
17.8.4. U.K. Cell Therapy Manufacturing Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast By Market Taxonomy
17.8.4.2.1. By Source
17.8.4.2.2. By Indication
17.8.4.2.3. By Manufacturing Purpose
17.8.4.2.4. By Route of Administration
17.8.4.2.5. By Cell Type
17.8.4.2.6. By End User
17.8.5. Spain Cell Therapy Manufacturing Market Analysis
17.8.5.1. Introduction
17.8.5.2. Market Analysis and Forecast By Market Taxonomy
17.8.5.2.1. By Source
17.8.5.2.2. By Indication
17.8.5.2.3. By Manufacturing Purpose
17.8.5.2.4. By Route of Administration
17.8.5.2.5. By Cell Type
17.8.5.2.6. By End User
17.8.6. BENELUX Cell Therapy Manufacturing Market Analysis
17.8.6.1. Introduction
17.8.6.2. Market Analysis and Forecast By Market Taxonomy
17.8.6.2.1. By Source
17.8.6.2.2. By Indication
17.8.6.2.3. By Manufacturing Purpose
17.8.6.2.4. By Route of Administration
17.8.6.2.5. By Cell Type
17.8.6.2.6. By End User
17.8.7. Nordic Countries & Russia Cell Therapy Manufacturing Market Analysis
17.8.7.1. Introduction
17.8.7.2. Market Analysis and Forecast By Market Taxonomy
17.8.7.2.1. By Source
17.8.7.2.2. By Indication
17.8.7.2.3. By Manufacturing Purpose
17.8.7.2.4. By Route of Administration
17.8.7.2.5. By Cell Type
17.8.7.2.6. By End User
18. East Asia Cell Therapy Manufacturing Market Analysis 2012–2021 and Forecast 2022–2032
18.1. Introduction
18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012–2021
18.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Source
18.3.3. By Indication
18.3.4. By Manufacturing Purpose
18.3.5. By Route of Administration
18.3.6. By Cell Type
18.3.7. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Source
18.4.3. By Indication
18.4.4. By Manufacturing Purpose
18.4.5. By Route of Administration
18.4.6. By Cell Type
18.4.7. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. China Cell Therapy Manufacturing Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast By Market Taxonomy
18.8.1.2.1. By Source
18.8.1.2.2. By Indication
18.8.1.2.3. By Manufacturing Purpose
18.8.1.2.4. By Route of Administration
18.8.1.2.5. By Cell Type
18.8.1.2.6. By End User
18.8.2. Japan Cell Therapy Manufacturing Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast By Market Taxonomy
18.8.2.2.1. By Source
18.8.2.2.2. By Indication
18.8.2.2.3. By Manufacturing Purpose
18.8.2.2.4. By Route of Administration
18.8.2.2.5. By Cell Type
18.8.2.2.6. By End User
18.8.3. South Korea Cell Therapy Manufacturing Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast By Market Taxonomy
18.8.3.2.1. By Source
18.8.3.2.2. By Indication
18.8.3.2.3. By Manufacturing Purpose
18.8.3.2.4. By Route of Administration
18.8.3.2.5. By Cell Type
18.8.3.2.6. By End User
19. South Asia Cell Therapy Manufacturing Market Analysis 2012–2021 and Forecast 2022–2032
19.1. Introduction
19.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012–2021
19.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032
19.3.1. By Country
19.3.1.1. India
19.3.1.2. Indonesia
19.3.1.3. Malaysia
19.3.1.4. Thailand
19.3.1.5. Rest of South Asia
19.3.2. By Source
19.3.3. By Indication
19.3.4. By Manufacturing Purpose
19.3.5. By Route of Administration
19.3.6. By Cell Type
19.3.7. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Source
19.4.3. By Indication
19.4.4. By Manufacturing Purpose
19.4.5. By Route of Administration
19.4.6. By Cell Type
19.4.7. By End User
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. India Cell Therapy Manufacturing Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast By Market Taxonomy
19.8.1.2.1. By Source
19.8.1.2.2. By Indication
19.8.1.2.3. By Manufacturing Purpose
19.8.1.2.4. By Route of Administration
19.8.1.2.5. By Cell Type
19.8.1.2.6. By End User
19.8.2. Indonesia Cell Therapy Manufacturing Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast By Market Taxonomy
19.8.2.2.1. By Source
19.8.2.2.2. By Indication
19.8.2.2.3. By Manufacturing Purpose
19.8.2.2.4. By Route of Administration
19.8.2.2.5. By Cell Type
19.8.2.2.6. By End User
19.8.3. Malaysia Cell Therapy Manufacturing Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast By Market Taxonomy
19.8.3.2.1. By Source
19.8.3.2.2. By Indication
19.8.3.2.3. By Manufacturing Purpose
19.8.3.2.4. By Route of Administration
19.8.3.2.5. By Cell Type
19.8.3.2.6. By End User
19.8.4. Thailand Cell Therapy Manufacturing Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast By Market Taxonomy
19.8.4.2.1. By Source
19.8.4.2.2. By Indication
19.8.4.2.3. By Manufacturing Purpose
19.8.4.2.4. By Route of Administration
19.8.4.2.5. By Cell Type
19.8.4.2.6. By End User
20. Oceania Cell Therapy Manufacturing Market 2012-2021 and Forecast 2022-2032
20.1. Introduction
20.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012–2021
20.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Source
20.3.3. By Indication
20.3.4. By Manufacturing Purpose
20.3.5. By Route of Administration
20.3.6. By Cell Type
20.3.7. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Source
20.4.3. By Indication
20.4.4. By Manufacturing Purpose
20.4.5. By Route of Administration
20.4.6. By Cell Type
20.4.7. By End User
20.5. Market Trends
20.6. Key Market Participants - Intensity Mapping
20.7. Drivers and Restraints - Impact Analysis
20.8. Country Level Analysis & Forecast
20.8.1. Australia Cell Therapy Manufacturing Market Analysis
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast By Market Taxonomy
20.8.1.2.1. By Source
20.8.1.2.2. By Indication
20.8.1.2.3. By Manufacturing Purpose
20.8.1.2.4. By Route of Administration
20.8.1.2.5. By Cell Type
20.8.1.2.6. By End User
20.8.2. New Zealand Cell Therapy Manufacturing Market Analysis
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast By Market Taxonomy
20.8.2.2.1. By Source
20.8.2.2.2. By Indication
20.8.2.2.3. By Manufacturing Purpose
20.8.2.2.4. By Route of Administration
20.8.2.2.5. By Cell Type
20.8.2.2.6. By End User
21. Middle East and Africa (MEA) Cell Therapy Manufacturing Market Analysis 2012–2021 and Forecast 2022–2032
21.1. Introduction
21.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2012–2021
21.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Turkey
21.3.1.3. South Africa
21.3.1.4. North Africa
21.3.1.5. Rest of Middle East and Africa
21.3.2. By Source
21.3.3. By Indication
21.3.4. By Manufacturing Purpose
21.3.5. By Route of Administration
21.3.6. By Cell Type
21.3.7. By End User
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Source
21.4.3. By Indication
21.4.4. By Manufacturing Purpose
21.4.5. By Route of Administration
21.4.6. By Cell Type
21.4.7. By End User
21.5. Market Trends
21.6. Key Market Participants - Intensity Mapping
21.7. Drivers and Restraints - Impact Analysis
21.8. Country Level Analysis & Forecast
21.8.1. GCC Countries Cell Therapy Manufacturing Market Analysis
21.8.1.1. Introduction
21.8.1.2. Market Analysis and Forecast By Market Taxonomy
21.8.1.2.1. By Source
21.8.1.2.2. By Indication
21.8.1.2.3. By Manufacturing Purpose
21.8.1.2.4. By Route of Administration
21.8.1.2.5. By Cell Type
21.8.1.2.6. By End User
21.8.2. Turkey Cell Therapy Manufacturing Market Analysis
21.8.2.1. Introduction
21.8.2.2. Market Analysis and Forecast By Market Taxonomy
21.8.2.2.1. By Source
21.8.2.2.2. By Indication
21.8.2.2.3. By Manufacturing Purpose
21.8.2.2.4. By Route of Administration
21.8.2.2.5. By Cell Type
21.8.2.2.6. By End User
21.8.3. South Africa Cell Therapy Manufacturing Market Analysis
21.8.3.1. Introduction
21.8.3.2. Market Analysis and Forecast By Market Taxonomy
21.8.3.2.1. By Source
21.8.3.2.2. By Indication
21.8.3.2.3. By Manufacturing Purpose
21.8.3.2.4. By Route of Administration
21.8.3.2.5. By Cell Type
21.8.3.2.6. By End User
21.8.4. North Africa Cell Therapy Manufacturing Market Analysis
21.8.4.1. Introduction
21.8.4.2. Market Analysis and Forecast By Market Taxonomy
21.8.4.2.1. By Source
21.8.4.2.2. By Indication
21.8.4.2.3. By Manufacturing Purpose
21.8.4.2.4. By Route of Administration
21.8.4.2.5. By Cell Type
21.8.4.2.6. By End User
22. Market Structure Analysis
22.1. Market Analysis By Tier of Companies
22.2. Market Concentration
22.3. Market Share Analysis (%) of Top Players
22.4. Market Presence Analysis
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
23.3.1. Merck KGaA
23.3.1.1. Overview
23.3.1.2. Source Portfolio
23.3.1.3. Sales Footprint
23.3.1.4. Key Financials
23.3.1.5. SWOT Analysis
23.3.1.6. Strategic Overview
23.3.2. Avantor, Inc.
23.3.2.1. Overview
23.3.2.2. Source Portfolio
23.3.2.3. Sales Footprint
23.3.2.4. Key Financials
23.3.2.5. SWOT Analysis
23.3.2.6. Strategic Overview
23.3.3. Cell Therapies Pty Ltd
23.3.3.1. Overview
23.3.3.2. Source Portfolio
23.3.3.3. Sales Footprint
23.3.3.4. Key Financials
23.3.3.5. SWOT Analysis
23.3.3.6. Strategic Overview
23.3.4. Thermo Fisher Scientific
23.3.4.1. Overview
23.3.4.2. Source Portfolio
23.3.4.3. Sales Footprint
23.3.4.4. Key Financials
23.3.4.5. SWOT Analysis
23.3.4.6. Strategic Overview
23.3.5. Charles River Laboratories
23.3.5.1. Overview
23.3.5.2. Source Portfolio
23.3.5.3. Sales Footprint
23.3.5.4. Key Financials
23.3.5.5. SWOT Analysis
23.3.5.6. Strategic Overview
23.3.6. Catalent, Inc
23.3.6.1. Overview
23.3.6.2. Source Portfolio
23.3.6.3. Sales Footprint
23.3.6.4. Key Financials
23.3.6.5. SWOT Analysis
23.3.6.6. Strategic Overview
23.3.7. Bio-Techne
23.3.7.1. Overview
23.3.7.2. Source Portfolio
23.3.7.3. Sales Footprint
23.3.7.4. Key Financials
23.3.7.5. SWOT Analysis
23.3.7.6. Strategic Overview
23.3.8. Cytiva
23.3.8.1. Overview
23.3.8.2. Source Portfolio
23.3.8.3. Sales Footprint
23.3.8.4. Key Financials
23.3.8.5. SWOT Analysis
23.3.8.6. Strategic Overview
23.3.9. Lonza
23.3.9.1. Overview
23.3.9.2. Source Portfolio
23.3.9.3. Sales Footprint
23.3.9.4. Key Financials
23.3.9.5. SWOT Analysis
23.3.9.6. Strategic Overview
23.3.10. The Discovery Labs
23.3.10.1. Overview
23.3.10.2. Source Portfolio
23.3.10.3. Sales Footprint
23.3.10.4. Key Financials
23.3.10.5. SWOT Analysis
23.3.10.6. Strategic Overview
23.3.11. BIOCENTRIQ
23.3.11.1. Overview
23.3.11.2. Source Portfolio
23.3.11.3. Sales Footprint
23.3.11.4. Key Financials
23.3.11.5. SWOT Analysis
23.3.11.6. Strategic Overview
23.3.12. FUJIFILM Diosynth Biotechnologies
23.3.12.1. Overview
23.3.12.2. Source Portfolio
23.3.12.3. Sales Footprint
23.3.12.4. Key Financials
23.3.12.5. SWOT Analysis
23.3.12.6. Strategic Overview
23.3.13. Novartis AG
23.3.13.1. Overview
23.3.13.2. Source Portfolio
23.3.13.3. Sales Footprint
23.3.13.4. Key Financials
23.3.13.5. SWOT Analysis
23.3.13.6. Strategic Overview
23.3.14. Bristol-Myers Squibb Company
23.3.14.1. Overview
23.3.14.2. Source Portfolio
23.3.14.3. Sales Footprint
23.3.14.4. Key Financials
23.3.14.5. SWOT Analysis
23.3.14.6. Strategic Overview
23.3.15. Gilead Sciences, Inc.
23.3.15.1. Overview
23.3.15.2. Source Portfolio
23.3.15.3. Sales Footprint
23.3.15.4. Key Financials
23.3.15.5. SWOT Analysis
23.3.15.6. Strategic Overview
23.3.16. WuXi AppTec.
23.3.16.1. Overview
23.3.16.2. Source Portfolio
23.3.16.3. Sales Footprint
23.3.16.4. Key Financials
23.3.16.5. SWOT Analysis
23.3.16.6. Strategic Overview
23.3.17. OXGENE
23.3.17.1. Overview
23.3.17.2. Source Portfolio
23.3.17.3. Sales Footprint
23.3.17.4. Key Financials
23.3.17.5. SWOT Analysis
23.3.17.6. Strategic Overview
23.3.18. Pharmaron
23.3.18.1. Overview
23.3.18.2. Source Portfolio
23.3.18.3. Sales Footprint
23.3.18.4. Key Financials
23.3.18.5. SWOT Analysis
23.3.18.6. Strategic Overview
23.3.19. Aldevron
23.3.19.1. Overview
23.3.19.2. Source Portfolio
23.3.19.3. Sales Footprint
23.3.19.4. Key Financials
23.3.19.5. SWOT Analysis
23.3.19.6. Strategic Overview
23.3.20. Exothera
23.3.20.1. Overview
23.3.20.2. Source Portfolio
23.3.20.3. Sales Footprint
23.3.20.4. Key Financials
23.3.20.5. SWOT Analysis
23.3.20.6. Strategic Overview
23.3.21. FLODESIGN SONICS
23.3.21.1. Overview
23.3.21.2. Source Portfolio
23.3.21.3. Sales Footprint
23.3.21.4. Key Financials
23.3.21.5. SWOT Analysis
23.3.21.6. Strategic Overview
24. Assumptions and Acronyms Used
25. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Source
Table 02: Global Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Indication
Table 03: Global Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Manufacturing Purpose
Table 04: Global Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Route of Administration
Table 05: Global Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Cell Type
Table 06: Global Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By End User
Table 07: Global Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Region
Table 08: North America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Country
Table 09: North America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Source
Table 10: North America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Indication
Table 11: North America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Manufacturing Purpose
Table 12: North America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Route of Administration
Table 13: North America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Cell Type
Table 14: North America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By End User
Table 15: Latin America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Country
Table 16: Latin America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Source
Table 17: Latin America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Indication
Table 18: Latin America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Manufacturing Purpose
Table 19: Latin America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Route of Administration
Table 20: Latin America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Cell Type
Table 21: Latin America Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By End User
Table 22: Europe Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Country
Table 23: Europe Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Source
Table 25: Europe Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Indication
Table 25: Europe Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Manufacturing Purpose
Table 26: Europe Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Route of Administration
Table 27: Europe Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Cell Type
Table 28: Europe Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By End User
Table 29: South Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Country
Table 30: South Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Source
Table 31: South Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Indication
Table 32: South Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Manufacturing Purpose
Table 33: South Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Route of Administration
Table 34: South Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Cell Type
Table 35: South Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By End User
Table 36: East Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Country
Table 37: East Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Source
Table 38: East Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Indication
Table 39: East Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Manufacturing Purpose
Table 40: East Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Route of Administration
Table 41: East Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Cell Type
Table 42: East Asia Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By End User
Table 43: Oceania Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Country
Table 44: Oceania Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Source
Table 45: Oceania Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Indication
Table 46: Oceania Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Manufacturing Purpose
Table 47: Oceania Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Route of Administration
Table 48: Oceania Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Cell Type
Table 49: Oceania Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By End User
Table 50: MEA Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Country
Table 51: MEA Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Source
Table 52: MEA Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Indication
Table 53: MEA Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Manufacturing Purpose
Table 54: MEA Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Route of Administration
Table 55: MEA Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By Cell Type
Table 56: MEA Cell Therapy Manufacturing Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2021-2031, By End User
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Cell Therapy Manufacturing Market Value Analysis (US$ Bn), 2012 – 2021
Figure 02: Global Cell Therapy Manufacturing Market Value Forecast (US$ Bn), 2022–2032
Figure 03: Global Cell Therapy Manufacturing Market Absolute $ Opportunity, 2022–2032
Figure 04: Global Cell Therapy Manufacturing Market Share Analysis (%), By Source, 2021 & 2032
Figure 05: Global Cell Therapy Manufacturing Market Y-o-Y Analysis (%), By Source, 2022–2032
Figure 06: Global Cell Therapy Manufacturing Market Attractiveness Analysis By Source, 2022–2032
Figure 07: Global Cell Therapy Manufacturing Market Share Analysis (%), By Indication, 2021 & 2032
Figure 08: Global Cell Therapy Manufacturing Market Y-o-Y Analysis (%), By Indication, 2022–2032
Figure 09: Global Cell Therapy Manufacturing Market Attractiveness Analysis By Indication, 2022–2032
Figure 10: Global Cell Therapy Manufacturing Market Share Analysis (%), By Manufacturing Purpose, 2022 & 2032
Figure 11: Global Cell Therapy Manufacturing Market Y-o-Y Analysis (%), By Manufacturing Purpose, 2022–2032
Figure 12: Global Cell Therapy Manufacturing Market Attractiveness Analysis By Manufacturing Purpose, 2022–2032
Figure 13: Global Cell Therapy Manufacturing Market Share Analysis (%), By Route of Administration, 2022 & 2032
Figure 14: Global Cell Therapy Manufacturing Market Y-o-Y Analysis (%), By Route of Administration, 2022–2032
Figure 15: Global Cell Therapy Manufacturing Market Attractiveness Analysis By Route of Administration, 2022–2032
Figure 16: Global Cell Therapy Manufacturing Market Share Analysis (%), By Cell Type, 2022 & 2032
Figure 17: Global Cell Therapy Manufacturing Market Y-o-Y Analysis (%), By Cell Type, 2022–2032
Figure 18: Global Cell Therapy Manufacturing Market Attractiveness Analysis By Cell Type, 2022–2032
Figure 19: Global Cell Therapy Manufacturing Market Share Analysis (%), By End User, 2022 & 2032
Figure 20: Global Cell Therapy Manufacturing Market Y-o-Y Analysis (%), By End User, 2022–2032
Figure 21: Global Cell Therapy Manufacturing Market Attractiveness Analysis By End User, 2022–2032
Figure 22: Global Cell Therapy Manufacturing Market Share Analysis (%), By Region, 2022 & 2032
Figure 23: Global Cell Therapy Manufacturing Market Y-o-Y Analysis (%), By Region, 2022–2032
Figure 24: Global Cell Therapy Manufacturing Market Attractiveness Analysis By Region, 2022–2032
Figure 25: North America Cell Therapy Manufacturing Market Split By Country, 2022 (E)
Figure 26: North America Cell Therapy Manufacturing Market Split By Source, 2022 (E)
Figure 27: North America Cell Therapy Manufacturing Market Split By Indication, 2022 (E)
Figure 28: North America Cell Therapy Manufacturing Market Split By Manufacturing Purpose, 2022 (E)
Figure 29: North America Cell Therapy Manufacturing Market Split By Route of Administration, 2022 (E)
Figure 30: North America Cell Therapy Manufacturing Market Split By Cell Type, 2022 (E)
Figure 31: North America Cell Therapy Manufacturing Market Split By End User, 2022 (E)
Figure 32: North America Cell Therapy Manufacturing Market Value Analysis (US$ Bn), 2012 – 2021
Figure 33: North America Cell Therapy Manufacturing Market Value Forecast (US$ Bn), 2022–2032
Figure 34: North America Cell Therapy Manufacturing Market Attractiveness Analysis By Source, 2022–2032
Figure 35: North America Cell Therapy Manufacturing Market Attractiveness Analysis By Indication, 2022–2032
Figure 36: North America Cell Therapy Manufacturing Market Attractiveness Analysis By Manufacturing Purpose, 2022–2032
Figure 37: North America Cell Therapy Manufacturing Market Attractiveness Analysis By Route of Administration, 2022–2032
Figure 38: North America Cell Therapy Manufacturing Market Attractiveness Analysis By Cell Type, 2022–2032
Figure 39: North America Cell Therapy Manufacturing Market Attractiveness Analysis By End User, 2022–2032
Figure 40: North America Cell Therapy Manufacturing Market Attractiveness Analysis By Country, 2022–2032
Figure 41: Canada Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 42: Canada Cell Therapy Manufacturing Market, Global Vs. Canada Growth Y-o-Y (%) Comparison, 2021–2032
Figure 43: Canada Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 44: Canada Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 45: Canada Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 46: Canada Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 47: Canada Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 48: Canada Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 49: U.S. Cell Therapy Manufacturing Market Split By Source, 2022 (E)
Figure 50: U.S. Cell Therapy Manufacturing Market Split By Indication, 2022 (E)
Figure 51: U.S. Cell Therapy Manufacturing Market Split By Manufacturing Purpose, 2022 (E)
Figure 52: U.S. Cell Therapy Manufacturing Market Split By Route of Administration, 2022 (E)
Figure 53: U.S. Cell Therapy Manufacturing Market Split By Cell Type, 2022 (E)
Figure 54: U.S. Cell Therapy Manufacturing Market Split By End User, 2022 (E)
Figure 55: U.S. Cell Therapy Manufacturing Market Value Analysis (US$ Bn), 2012 – 2021
Figure 56: U.S. Cell Therapy Manufacturing Market Value Forecast (US$ Bn), 2022–2032
Figure 57: U.S. Cell Therapy Manufacturing Market Attractiveness Analysis By Source, 2022–2032
Figure 58: U.S. Cell Therapy Manufacturing Market Attractiveness Analysis By Indication, 2022–2032
Figure 59: U.S. Cell Therapy Manufacturing Market Attractiveness Analysis By Manufacturing Purpose, 2022–2032
Figure 60: U.S. Cell Therapy Manufacturing Market Attractiveness Analysis By Route of Administration, 2022–2032
Figure 61: U.S. Cell Therapy Manufacturing Market Attractiveness Analysis By Cell Type, 2022–2032
Figure 62: U.S. Cell Therapy Manufacturing Market Attractiveness Analysis By End User, 2022–2032
Figure 63: Latin America Cell Therapy Manufacturing Market Split By Country, 2022 (E)
Figure 64: Latin America Cell Therapy Manufacturing Market Split By Source, 2022 (E)
Figure 65: Latin America Cell Therapy Manufacturing Market Split By Indication, 2022 (E)
Figure 66: Latin America Cell Therapy Manufacturing Market Split By Manufacturing Purpose, 2022 (E)
Figure 67: Latin America Cell Therapy Manufacturing Market Split By Route of Administration, 2022 (E)
Figure 68: Latin America Cell Therapy Manufacturing Market Split By Cell Type, 2022 (E)
Figure 69: Latin America Cell Therapy Manufacturing Market Split By End User, 2022 (E)
Figure 70: Latin America Cell Therapy Manufacturing Market Value Analysis (US$ Bn), 2012 – 2021
Figure 71: Latin America Cell Therapy Manufacturing Market Value Forecast (US$ Bn), 2022–2032
Figure 72: Latin America Cell Therapy Manufacturing Market Attractiveness Analysis By Source, 2022–2032
Figure 73: Latin America Cell Therapy Manufacturing Market Attractiveness Analysis By Indication, 2022–2032
Figure 74: Latin America Cell Therapy Manufacturing Market Attractiveness Analysis By Manufacturing Purpose, 2022–2032
Figure 75: Latin America Cell Therapy Manufacturing Market Attractiveness Analysis By Route of Administration, 2022–2032
Figure 76: Latin America Cell Therapy Manufacturing Market Attractiveness Analysis By Cell Type, 2022–2032
Figure 77: Latin America Cell Therapy Manufacturing Market Attractiveness Analysis By End User, 2022–2032
Figure 78: Latin America Cell Therapy Manufacturing Market Attractiveness Analysis By Country, 2022–2032
Figure 79: Brazil Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 80: Brazil Cell Therapy Manufacturing Market, Global Vs. Brazil Growth Y-o-Y (%) Comparison, 2021–2032
Figure 81: Brazil Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 82: Brazil Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 83: Brazil Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 84: Brazil Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 85: Brazil Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 86: Brazil Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 87: Mexico Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 88: Mexico Cell Therapy Manufacturing Market, Global Vs. Mexico Growth Y-o-Y (%) Comparison, 2021–2032
Figure 89: Mexico Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 90: Mexico Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 91: Mexico Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 92: Mexico Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 93: Mexico Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 94: Mexico Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 95: Argentina Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 96: Argentina Cell Therapy Manufacturing Market, Global Vs. Argentina Growth Y-o-Y (%) Comparison, 2021–2032
Figure 97: Argentina Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 98: Argentina Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 99: Argentina Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 100: Argentina Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 101: Argentina Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 102: Argentina Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 103: Europe Cell Therapy Manufacturing Market Split By Country, 2022 (E)
Figure 104: Europe Cell Therapy Manufacturing Market Split By Source, 2022 (E)
Figure 105: Europe Cell Therapy Manufacturing Market Split By Indication, 2022 (E)
Figure 106: Europe Cell Therapy Manufacturing Market Split By Manufacturing Purpose, 2022 (E)
Figure 107: Europe Cell Therapy Manufacturing Market Split By Route of Administration, 2022 (E)
Figure 108: Europe Cell Therapy Manufacturing Market Split By Cell Type, 2022 (E)
Figure 109: Europe Cell Therapy Manufacturing Market Split By End User, 2022 (E)
Figure 110: Europe Cell Therapy Manufacturing Market Value Analysis (US$ Bn), 2012 – 2021
Figure 111: Europe Cell Therapy Manufacturing Market Value Forecast (US$ Bn), 2022–2032
Figure 112: Europe Cell Therapy Manufacturing Market Attractiveness Analysis By Source, 2022–2032
Figure 113: Europe Cell Therapy Manufacturing Market Attractiveness Analysis By Indication, 2022–2032
Figure 114: Europe Cell Therapy Manufacturing Market Attractiveness Analysis By Manufacturing Purpose, 2022–2032
Figure 115: Europe Cell Therapy Manufacturing Market Attractiveness Analysis By Route of Administration, 2022–2032
Figure 116: Europe Cell Therapy Manufacturing Market Attractiveness Analysis By Cell Type, 2022–2032
Figure 117: Europe Cell Therapy Manufacturing Market Attractiveness Analysis By End User, 2022–2032
Figure 118: Europe Cell Therapy Manufacturing Market Attractiveness Analysis By Country, 2022–2032
Figure 119: U.K. Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 120: U.K. Cell Therapy Manufacturing Market, Global Vs. U.K. Growth Y-o-Y (%) Comparison, 2021–2032
Figure 121: U.K. Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 122: U.K. Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 123: U.K. Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 124: U.K. Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 125: U.K. Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 126: U.K. Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 127: Germany Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 128: Germany Cell Therapy Manufacturing Market, Global Vs. Germany Growth Y-o-Y (%) Comparison, 2021–2032
Figure 129: Germany Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 130: Germany Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 131: Germany Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 132: Germany Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 133: Germany Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 134: Germany Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 135: Italy Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 136: Italy Cell Therapy Manufacturing Market, Global Vs. Italy Growth Y-o-Y (%) Comparison, 2021–2032
Figure 137: Italy Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 138: Italy Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 139: Italy Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 140: Italy Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 141: Italy Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 142: Italy Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 143: France Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 144: France Cell Therapy Manufacturing Market, Global Vs. France Growth Y-o-Y (%) Comparison, 2021–2032
Figure 145: France Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 146: France Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 147: France Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 148: France Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 149: France Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 150: France Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 151: Spain Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 152: Spain Cell Therapy Manufacturing Market, Global Vs. Spain Growth Y-o-Y (%) Comparison, 2021–2032
Figure 153: Spain Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 154: Spain Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 155: Spain Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 156: Spain Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 157: Spain Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 158: Spain Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 159: Russia Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 160: Russia Cell Therapy Manufacturing Market, Global Vs. Russia Growth Y-o-Y (%) Comparison, 2021–2032
Figure 161: Russia Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 162: Russia Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 163: Russia Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 164: Russia Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 165: Russia Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 166: Russia Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 167: BENULUX Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 168: BENULUX Cell Therapy Manufacturing Market, Global Vs. BENULUX Growth Y-o-Y (%) Comparison, 2021–2032
Figure 169: BENULUX Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 170: BENULUX Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 171: BENULUX Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 172: BENULUX Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 173: BENULUX Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 174: BENULUX Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 175: South Asia Cell Therapy Manufacturing Market Split By Country, 2022 (E)
Figure 176: South Asia Cell Therapy Manufacturing Market Split By Source, 2022 (E)
Figure 177: South Asia Cell Therapy Manufacturing Market Split By Indication, 2022 (E)
Figure 178: South Asia Cell Therapy Manufacturing Market Split By Manufacturing Purpose, 2022 (E)
Figure 179: South Asia Cell Therapy Manufacturing Market Split By Route of Administration, 2022 (E)
Figure 180: South Asia Cell Therapy Manufacturing Market Split By Cell Type, 2022 (E)
Figure 181: South Asia Cell Therapy Manufacturing Market Split By End User, 2022 (E)
Figure 182: South Asia Cell Therapy Manufacturing Market Value Analysis (US$ Bn), 2012 – 2021
Figure 183: South Asia Cell Therapy Manufacturing Market Value Forecast (US$ Bn), 2022–2032
Figure 184: South Asia Cell Therapy Manufacturing Market Attractiveness Analysis By Source, 2022–2032
Figure 185: South Asia Cell Therapy Manufacturing Market Attractiveness Analysis By Indication, 2022–2032
Figure 186: South Asia Cell Therapy Manufacturing Market Attractiveness Analysis By Manufacturing Purpose, 2022–2032
Figure 187: South Asia Cell Therapy Manufacturing Market Attractiveness Analysis By Route of Administration, 2022–2032
Figure 188: South Asia Cell Therapy Manufacturing Market Attractiveness Analysis By Cell Type, 2022–2032
Figure 189: South Asia Cell Therapy Manufacturing Market Attractiveness Analysis By End User, 2022–2032
Figure 190: South Asia Cell Therapy Manufacturing Market Attractiveness Analysis By Country, 2022–2032
Figure 191: India Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 192: India Cell Therapy Manufacturing Market, Global Vs. India Growth Y-o-Y (%) Comparison, 2021–2032
Figure 193: India Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 194: India Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 195: India Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 196: India Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 197: India Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 198: India Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 199: Malaysia Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 200: Malaysia Cell Therapy Manufacturing Market, Global Vs. Malaysia Growth Y-o-Y (%) Comparison, 2021–2032
Figure 201: Malaysia Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 202: Malaysia Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 203: Malaysia Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 204: Malaysia Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 205: Malaysia Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 206: Malaysia Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 207: Thailand Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 208: Thailand Cell Therapy Manufacturing Market, Global Vs. Thailand Growth Y-o-Y (%) Comparison, 2021–2032
Figure 209: Thailand Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 210: Thailand Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 211: Thailand Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 212: Thailand Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 213: Thailand Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 214: Thailand Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 215: Indonesia Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 216: Indonesia Cell Therapy Manufacturing Market, Global Vs. Indonesia Growth Y-o-Y (%) Comparison, 2021–2032
Figure 217: Indonesia Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 218: Indonesia Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 219: Indonesia Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 220: Indonesia Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 221: Indonesia Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 222: Indonesia Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 223: East Asia Cell Therapy Manufacturing Market Split By Country, 2022 (E)
Figure 224: East Asia Cell Therapy Manufacturing Market Split By Source, 2022 (E)
Figure 225: East Asia Cell Therapy Manufacturing Market Split By Indication, 2022 (E)
Figure 226: East Asia Cell Therapy Manufacturing Market Split By Manufacturing Purpose, 2022 (E)
Figure 227: East Asia Cell Therapy Manufacturing Market Split By Route of Administration, 2022 (E)
Figure 228: East Asia Cell Therapy Manufacturing Market Split By Cell Type, 2022 (E)
Figure 229: East Asia Cell Therapy Manufacturing Market Split By End User, 2022 (E)
Figure 230: East Asia Cell Therapy Manufacturing Market Value Analysis (US$ Bn), 2012 – 2021
Figure 231: East Asia Cell Therapy Manufacturing Market Value Forecast (US$ Bn), 2022–2032
Figure 232: East Asia Cell Therapy Manufacturing Market Attractiveness Analysis By Source, 2022–2032
Figure 233: East Asia Cell Therapy Manufacturing Market Attractiveness Analysis By Indication, 2022–2032
Figure 234: East Asia Cell Therapy Manufacturing Market Attractiveness Analysis By Manufacturing Purpose, 2022–2032
Figure 235: East Asia Cell Therapy Manufacturing Market Attractiveness Analysis By Route of Administration, 2022–2032
Figure 236: East Asia Cell Therapy Manufacturing Market Attractiveness Analysis By Cell Type, 2022–2032
Figure 237: East Asia Cell Therapy Manufacturing Market Attractiveness Analysis By End User, 2022–2032
Figure 238: East Asia Cell Therapy Manufacturing Market Attractiveness Analysis By Country, 2022–2032
Figure 239: China Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 240: China Cell Therapy Manufacturing Market, Global Vs. China Growth Y-o-Y (%) Comparison, 2021–2032
Figure 241: China Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 242: China Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 243: China Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 244: China Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 245: China Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 246: China Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 247: Japan Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 248: Japan Cell Therapy Manufacturing Market, Global Vs. Japan Growth Y-o-Y (%) Comparison, 2021–2032
Figure 249: Japan Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 250: Japan Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 251: Japan Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 252: Japan Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 253: Japan Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 254: Japan Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 255: South Korea Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 256: South Korea Cell Therapy Manufacturing Market, Global Vs. South Korea Growth Y-o-Y (%) Comparison, 2021–2032
Figure 257: South Korea Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 258: South Korea Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 259: South Korea Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 260: South Korea Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 261: South Korea Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 262: South Korea Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 263: Oceania Cell Therapy Manufacturing Market Split By Country, 2022 (E)
Figure 264: Oceania Cell Therapy Manufacturing Market Split By Source, 2022 (E)
Figure 265: Oceania Cell Therapy Manufacturing Market Split By Indication, 2022 (E)
Figure 266: Oceania Cell Therapy Manufacturing Market Split By Manufacturing Purpose, 2022 (E)
Figure 267: Oceania Cell Therapy Manufacturing Market Split By Route of Administration, 2022 (E)
Figure 268: Oceania Cell Therapy Manufacturing Market Split By Cell Type, 2022 (E)
Figure 269: Oceania Cell Therapy Manufacturing Market Split By End User, 2022 (E)
Figure 270: Oceania Cell Therapy Manufacturing Market Value Analysis (US$ Bn), 2012 – 2021
Figure 271: Oceania Cell Therapy Manufacturing Market Value Forecast (US$ Bn), 2022–2032
Figure 272: Oceania Cell Therapy Manufacturing Market Attractiveness Analysis By Source, 2022–2032
Figure 273: Oceania Cell Therapy Manufacturing Market Attractiveness Analysis By Indication, 2022–2032
Figure 274: Oceania Cell Therapy Manufacturing Market Attractiveness Analysis By Manufacturing Purpose, 2022–2032
Figure 275: Oceania Cell Therapy Manufacturing Market Attractiveness Analysis By Route of Administration, 2022–2032
Figure 276: Oceania Cell Therapy Manufacturing Market Attractiveness Analysis By Cell Type, 2022–2032
Figure 277: Oceania Cell Therapy Manufacturing Market Attractiveness Analysis By End User, 2022–2032
Figure 278: Oceania Cell Therapy Manufacturing Market Attractiveness Analysis By Country, 2022–2032
Figure 279: Australia Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 280: Australia Cell Therapy Manufacturing Market, Global Vs. Australia Growth Y-o-Y (%) Comparison, 2021–2032
Figure 281: Australia Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 282: Australia Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 283: Australia Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 284: Australia Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 285: Australia Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 286: Australia Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 287: New Zealand Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 288: New Zealand Cell Therapy Manufacturing Market, Global Vs. New Zealand Growth Y-o-Y (%) Comparison, 2021–2032
Figure 289: New Zealand Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 290: New Zealand Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 291: New Zealand Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 292: New Zealand Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 293: New Zealand Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 294: New Zealand Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 295: Middle East and Africa Cell Therapy Manufacturing Market Split By Country, 2022 (E)
Figure 296: Middle East and Africa Cell Therapy Manufacturing Market Split By Source, 2022 (E)
Figure 297: Middle East and Africa Cell Therapy Manufacturing Market Split By Indication, 2022 (E)
Figure 298: Middle East and Africa Cell Therapy Manufacturing Market Split By Manufacturing Purpose, 2022 (E)
Figure 299: Middle East and Africa Cell Therapy Manufacturing Market Split By Route of Administration, 2022 (E)
Figure 300: Middle East and Africa Cell Therapy Manufacturing Market Split By Cell Type, 2022 (E)
Figure 301: Middle East and Africa Cell Therapy Manufacturing Market Split By End User, 2022 (E)
Figure 302: Middle East and Africa Cell Therapy Manufacturing Market Value Analysis (US$ Bn), 2012 – 2021
Figure 303: Middle East and Africa Cell Therapy Manufacturing Market Value Forecast (US$ Bn), 2022–2032
Figure 304: Middle East and Africa Cell Therapy Manufacturing Market Attractiveness Analysis By Source, 2022–2032
Figure 305: Middle East and Africa Cell Therapy Manufacturing Market Attractiveness Analysis By Indication, 2022–2032
Figure 306: Middle East and Africa Cell Therapy Manufacturing Market Attractiveness Analysis By Manufacturing Purpose, 2022–2032
Figure 307: Middle East and Africa Cell Therapy Manufacturing Market Attractiveness Analysis By Route of Administration, 2022–2032
Figure 308: Middle East and Africa Cell Therapy Manufacturing Market Attractiveness Analysis By Cell Type, 2022–2032
Figure 309: Middle East and Africa Cell Therapy Manufacturing Market Attractiveness Analysis By End User, 2022–2032
Figure 310: Middle East and Africa Cell Therapy Manufacturing Market Attractiveness Analysis By Country, 2022–2032
Figure 311: Turkey Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 312: Turkey Cell Therapy Manufacturing Market, Global Vs. Turkey Growth Y-o-Y (%) Comparison, 2021–2032
Figure 313: Turkey Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 314: Turkey Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 315: Turkey Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 316: Turkey Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 317: Turkey Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 318: Turkey Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 319: GCC Countries Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 320: GCC Countries Cell Therapy Manufacturing Market, Global Vs. GCC Countries Growth Y-o-Y (%) Comparison, 2021–2032
Figure 321: GCC Countries Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 322: GCC Countries Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 323: GCC Countries Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 324: GCC Countries Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 325: GCC Countries Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 326: GCC Countries Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 327: South Africa Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 328: South Africa Cell Therapy Manufacturing Market, Global Vs. South Africa Growth Y-o-Y (%) Comparison, 2021–2032
Figure 329: South Africa Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 330: South Africa Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 331: South Africa Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 332: South Africa Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 333: South Africa Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 334: South Africa Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Figure 335: North Africa Cell Therapy Manufacturing Market Value Proportion Analysis, 2021
Figure 336: North Africa Cell Therapy Manufacturing Market, Global Vs. North Africa Growth Y-o-Y (%) Comparison, 2021–2032
Figure 337: North Africa Cell Therapy Manufacturing Market Share Analysis (%) By Source, 2021 & 2032
Figure 338: North Africa Cell Therapy Manufacturing Market Share Analysis (%) By Indication, 2021 & 2032
Figure 339: North Africa Cell Therapy Manufacturing Market Share Analysis (%) By Manufacturing Purpose, 2021 & 2032
Figure 340: North Africa Cell Therapy Manufacturing Market Share Analysis (%) By Route of Administration, 2021 & 2032
Figure 341: North Africa Cell Therapy Manufacturing Market Share Analysis (%) By Cell Type, 2021 & 2032
Figure 342: North Africa Cell Therapy Manufacturing Market Share Analysis (%) By End User, 2021 & 2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
